Immuno-oncology
Conference Coverage
Preclinical findings highlight value of Lynch syndrome for cancer vaccine development
ATLANTA – Lynch syndrome is serving as a platform for the development of immunoprevention cancer vaccines.
Conference Coverage
CAR T cells target HER2 expression in advanced sarcomas
ATLANTA – Although HER2 expression in osteosarcoma and rhabomyosarcoma is too low for HER2-targeted therapies such...
Conference Coverage
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLC
SAN FRANCISCO – The 6-month PFS rates were similar for patients treated every 2 or 4 weeks, but the trial could not show noninferiority of...
Conference Coverage
Diet appears to play an important role in response to anti-PD-1 cancer immunotherapy
Diet appears to affect response to anti-PD-1 cancer immunotherapy, likely by its effect on the gut microbiome.
Conference Coverage
First-line avelumab/axitinib for RCC benefits wide range of patients
SAN FRANCISCO – Subgroup analyses of the JAVELIN Renal 101 trial show that first-line avelumab/axitinib yields better PFS and ORRs than sunitinib...
Article
The Use of Immuno-Oncology Treatments in the VA
News
Azacitidine-nivolumab combo 'encouraging' in AML
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.
News
Checkpoint inhibitor doubles 3-year survival rate of BRAF wild-type advanced melanoma
The 3-year overall survival rate for patients treated with nivolumab was 51.2%, compared with 21.6% for those who received dacarbazine.
Conference Coverage
Checkpoint inhibitor seems safe and effective for patients with HIV
MUNICH – No immune-related adverse events or deaths due to drug toxicity occurred in cancer patients with HIV treated with nivolumab.
Conference Coverage
Checkpoint inhibitor/TKI combo improves PFS of RCC over sunitinib
MUNICH – Avelumab and axitinib offered better progression-free survival than did sunitinib as first-line therapy for advanced renal cell carcinoma...